Akari Therapeutics Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Akari Therapeutics Plc on November 19, 2015. The report details the approval and implementation of a new non-executive director compensation policy effective November 19, 2015, following recommendations from the Compensation Committee and an independent consultant.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on governance and compensation matters.
Material Changes
The primary material change is the adoption of an amended and restated non-employee director compensation policy. Key components of the new policy include:
- Annual Retainers: $36,000 for board service; $5,000 for committee membership; $10,000 for committee chairs (except Audit); $15,000 for the Audit Committee chair.
- Equity Grants: Annual grants of options to purchase 1,300,000 ordinary shares for continuing directors (vesting in one year) and initial grants of 1,300,000 shares for new directors (vesting ratably over three years).
- Payment Election: Directors may elect to receive fully-vested ordinary shares in lieu of cash retainers.
- Specific Grants: On November 25, 2015, the board approved additional option grants to specific directors: Mark Cohen (1,028,722 shares), Stuart Ungar (1,088,722 shares), James Hill (1,068,722 shares), and Allan Shaw (1,068,722 shares). These vest on the earlier of the next annual meeting or the one-year anniversary.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. No specific risks or contingencies are disclosed in this report other than the standard vesting conditions tied to continued service and change of control provisions.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2014 Equity Incentive Plan to assess the impact of the new 1,300,000 share annual grants per director.
- Confirm the fair market value of ordinary shares on November 25, 2015, to determine the exercise price of the specific grants to Cohen, Ungar, Hill, and Shaw.
- Review the full text of Exhibit 10.1 for detailed terms regarding the election of shares in lieu of cash and change of control acceleration.
- Check subsequent filings for the actual vesting dates of the November 2015 grants relative to the company's next annual shareholder meeting.